Document is current

Article History

Received: 8 January 2025

Accepted: 13 January 2025

First Online: 27 January 2025

Declarations

:

: This study used Health Insurance Portability and Accountability Act–compliant and deidentified data, which did not meet the criteria for human subject research as specified in the United States Department of Health and Human Services 45 Code of Federal Regulations Part 46. Therefore, neither institutional review board approval nor informed consent was required.

: Not applicable.

: • SD reports consulting for Pfizer Inc., AstraZeneca, Gilead Sciences, Myocardial Solutions, Novartis, and Lilly.• AG reports being a ZERO Cancer Health Equity Task Force member; American Heart Association Council on Clinical Cardiology and Genomics and Precision Medicine Cardio-Oncology Committee member and site principal investigator; and an advisory board member for Myovant, Pfizer Inc., and Novartis.• HM reports consulting for Novartis, Lilly, AstraZeneca, Gilead, Genetech, and Pfizer Inc.• DM, RM, IA, and BL are employees of, and stockholders in, Pfizer Inc.• SS is an employee of and stockholder in Pfizer Inc., and a stockholder in Roche.• MF reports grant support from Medtronic and AstraZeneca; and has consulted for AstraZeneca, AbbVie, Johnson & Johnson, Janssen, Pfizer Inc., and Zoll.